These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8722075)

  • 1. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients.
    Rakotoambinina B; Timsit J; Deschamps I; Laborde K; Jos J; Boitard C; Assan R; Robert JJ
    Diabetes Care; 1995 Nov; 18(11):1487-90. PubMed ID: 8722075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ; Prigeon RL; D'Alessio DA
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished insulin secretory response to glucose but normal insulin and glucagon secretory responses to arginine in a family with maternally inherited diabetes and deafness caused by mitochondrial tRNA(LEU(UUR)) gene mutation.
    Brändle M; Lehmann R; Maly FE; Schmid C; Spinas GA
    Diabetes Care; 2001 Jul; 24(7):1253-8. PubMed ID: 11423511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginine-induced insulin release in glucokinase-deficient subjects.
    Pueyo ME; Clement K; Vaxillaire M; Passa P; Froguel P; Robert JJ; Velho G
    Diabetes Care; 1994 Sep; 17(9):1015-21. PubMed ID: 7988299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-glucose (GG) test for the estimation of the insulin reserve in diabetes.
    Miki H; Matsuyama T; Fujii S; Komatsu R; Nishioeda Y; Omae T
    Diabetes Res Clin Pract; 1992 Nov; 18(2):99-105. PubMed ID: 1478158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients.
    Pfeffer F; Nauck MA; Benz S; Gwodzinski A; Zink R; Büsing M; Becker HD; Hopt UT
    Diabetologia; 1996 Apr; 39(4):462-8. PubMed ID: 8777996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients.
    Burcelin RG; Eddouks M; Beylot M; Normand S; Boitard C; Feutren G; Landais P; Riou JP; Girard JR; Bach JF
    Diabetes Care; 1993 Jun; 16(6):881-8. PubMed ID: 8325202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
    Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
    Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine.
    Dupre J; Jenner MR; Mahon JL; Purdon C; Rodger NW; Stiller CR
    Diabetes; 1991 May; 40(5):598-604. PubMed ID: 2022304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction.
    Stumvoll M; Fritsche A; Stefan N; Hardt E; Häring H
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1235-9. PubMed ID: 11238514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles.
    Alejandro R; Feldman EC; Bloom AD; Kenyon NS
    Diabetes; 1989 Jun; 38(6):698-703. PubMed ID: 2656339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of beta cell failure after prolonged remission of insulin-dependent diabetes mellitus (IDDM).
    Drucker D; Zinman B
    Diabetes Care; 1984; 7(1):83-7. PubMed ID: 6423354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased peripheral venous somatostatin concentration and decreased glucagon response to arginine in patients with insulin dependent diabetes mellitus without residual B-cell function. Increased plasma SRIF in IDDM.
    Skare S; Dahl-Jørgensen K; Hanssen KF; Norman N
    Acta Endocrinol (Copenh); 1985 Aug; 109(4):517-21. PubMed ID: 2863913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.
    Solomon TP; Knudsen SH; Karstoft K; Winding K; Holst JJ; Pedersen BK
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4682-91. PubMed ID: 23043193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of an oral mixed meal plus arginine and intravenous glucose, GLP-1 plus arginine to unmask residual islet function in longstanding type 1 diabetes.
    Uitbeijerse BS; Nijhoff MF; de Koning EJP
    Am J Physiol Endocrinol Metab; 2024 May; 326(5):E673-E680. PubMed ID: 38446636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.